Hims & Hers stock falls
Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...
Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...
6don MSN
Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...
HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...
Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Analysts are buzzing as well, with TD Cowen raising its price target to $28, citing HIMS' diverse revenue streams and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback